• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长链非编码RNA在癌症耐药中的调控作用

The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance.

作者信息

Askarian-Amiri Marjan E, Leung Euphemia, Finlay Graeme, Baguley Bruce C

机构信息

Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.

Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

出版信息

Methods Mol Biol. 2016;1395:207-27. doi: 10.1007/978-1-4939-3347-1_12.

DOI:10.1007/978-1-4939-3347-1_12
PMID:26910076
Abstract

Recent genomic and transcriptomic analysis has revealed that the majority of the human genome is transcribed as nonprotein-coding RNA. These transcripts, known as long noncoding RNA, have structures similar to those of mRNA. Many of these transcripts are now thought to have regulatory roles in different biological pathways which provide cells with an additional layer of regulatory complexity in gene expression and proteome function in response to stimuli. A wide variety of cellular functions may thus depend on the fine-tuning of interactions between noncoding RNAs and other key molecules in cell signaling networks. Deregulation of many noncoding RNAs is thought to occur in a variety of human diseases, including neoplasia and cancer drug resistance. Here we discuss recent findings on the molecular functions of long noncoding RNAs in cellular pathways mediating resistance to anticancer drugs.

摘要

最近的基因组和转录组分析表明,人类基因组的大部分转录为非蛋白质编码RNA。这些转录本,即长链非编码RNA,其结构与mRNA相似。现在认为,其中许多转录本在不同的生物学途径中具有调控作用,这为细胞在基因表达和蛋白质组功能方面提供了额外一层的调控复杂性,以响应刺激。因此,多种细胞功能可能依赖于细胞信号网络中非编码RNA与其他关键分子之间相互作用的微调。许多非编码RNA的失调被认为发生在多种人类疾病中,包括肿瘤形成和癌症耐药性。在这里,我们讨论了长链非编码RNA在介导抗癌药物耐药性的细胞途径中的分子功能的最新发现。

相似文献

1
The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance.长链非编码RNA在癌症耐药中的调控作用
Methods Mol Biol. 2016;1395:207-27. doi: 10.1007/978-1-4939-3347-1_12.
2
Long noncoding RNAs in normal and pathological pluripotency.正常及病理多能性中的长链非编码RNA
Semin Cell Dev Biol. 2017 May;65:1-10. doi: 10.1016/j.semcdb.2016.07.011. Epub 2016 Jul 18.
3
Noncoding RNAs in Cancer Cell Plasticity.癌细胞可塑性中的非编码RNA
Adv Exp Med Biol. 2016;927:173-89. doi: 10.1007/978-981-10-1498-7_6.
4
Long non-coding RNAs regulate drug resistance in cancer.长非编码 RNA 调控癌症的药物耐药性。
Mol Cancer. 2020 Mar 12;19(1):54. doi: 10.1186/s12943-020-01162-0.
5
Long non-coding RNAs in cancer drug resistance development.癌症耐药性发展中的长链非编码RNA
DNA Repair (Amst). 2016 Sep;45:25-33. doi: 10.1016/j.dnarep.2016.06.003. Epub 2016 Jun 30.
6
Noncoding RNAs in Regulation of Cancer Metabolic Reprogramming.非编码RNA在癌症代谢重编程调控中的作用
Adv Exp Med Biol. 2016;927:191-215. doi: 10.1007/978-981-10-1498-7_7.
7
Long noncoding RNAs as biotargets in cisplatin-based drug resistance.长链非编码 RNA 作为顺铂类药物耐药性的生物靶点。
Future Oncol. 2018 Dec;14(29):3085-3095. doi: 10.2217/fon-2018-0303. Epub 2018 Nov 23.
8
Mechanism of cancer drug resistance and the involvement of noncoding RNAs.癌症药物耐药性的机制与非编码 RNA 的参与。
Curr Med Chem. 2014;21(26):3029-41. doi: 10.2174/0929867321666140414101939.
9
Noncoding RNAs in Therapeutic Resistance of Cancer.非编码RNA在癌症治疗耐药性中的作用
Adv Exp Med Biol. 2016;927:265-95. doi: 10.1007/978-981-10-1498-7_10.
10
Long noncoding RNAs: regulation, function and cancer.长非编码 RNA:调控、功能与癌症。
Biotechnol Genet Eng Rev. 2018 Oct;34(2):153-180. doi: 10.1080/02648725.2018.1471566. Epub 2018 Aug 3.

引用本文的文献

1
The Emerging Role of Long Non-Coding RNAs in Esophageal Cancer: Functions in Tumorigenesis and Clinical Implications.长链非编码RNA在食管癌中的新兴作用:在肿瘤发生中的功能及临床意义
Front Pharmacol. 2022 May 13;13:885075. doi: 10.3389/fphar.2022.885075. eCollection 2022.
2
Retracted Article: Long non-coding RNA GACAT1 alleviates doxorubicin and vincristine resistance through a PTEN/AKT/mTOR/S6K1 regulatory pathway in gastric cancer.撤稿文章:长链非编码RNA GACAT1通过PTEN/AKT/mTOR/S6K1调控通路减轻胃癌对多柔比星和长春新碱的耐药性
RSC Adv. 2019 Mar 11;9(14):8048-8055. doi: 10.1039/c8ra10030f. eCollection 2019 Mar 6.
3
Decoding LncRNAs.
长链非编码核糖核酸的解码
Cancers (Basel). 2021 May 27;13(11):2643. doi: 10.3390/cancers13112643.
4
EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.在他莫昔芬耐药的MCF-7细胞中敲低EZH2可揭示恢复对他莫昔芬敏感性的新靶点。
Breast Cancer. 2021 Mar;28(2):355-367. doi: 10.1007/s12282-020-01166-0. Epub 2020 Sep 29.
5
Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer.长链非编码RNA介导的非小细胞肺癌耐药机制
Cancer Gene Ther. 2021 Apr;28(3-4):175-187. doi: 10.1038/s41417-020-00214-3. Epub 2020 Aug 25.
6
Long non-coding RNA HANR as a biomarker for the diagnosis and prognosis of colorectal cancer.长链非编码RNA HANR作为结直肠癌诊断和预后的生物标志物
Medicine (Baltimore). 2020 Feb;99(7):e19066. doi: 10.1097/MD.0000000000019066.
7
Long Noncoding RNA (lncRNA) FOXD2-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Regulating MiR-185/AKT Axis.长链非编码 RNA (lncRNA) FOXD2-AS1 通过调节 miR-185/AKT 轴促进肝癌细胞增殖和转移。
Med Sci Monit. 2019 Dec 16;25:9618-9629. doi: 10.12659/MSM.918230.
8
Long non-coding RNA TUG1 mediates 5-fluorouracil resistance by acting as a ceRNA of miR-197-3p in colorectal cancer.长链非编码RNA TUG1通过作为miR-197-3p的竞争性内源RNA在结直肠癌中介导5-氟尿嘧啶耐药。
J Cancer. 2019 Aug 7;10(19):4603-4613. doi: 10.7150/jca.32065. eCollection 2019.
9
Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.非编码RNA:转录组之谜及其在癌症中的前景
Ann Transl Med. 2018 Jun;6(12):241. doi: 10.21037/atm.2018.06.10.
10
Vesiculated Long Non-Coding RNAs: Offshore Packages Deciphering Trans-Regulation between Cells, Cancer Progression and Resistance to Therapies.囊泡化长链非编码RNA:解读细胞间、癌症进展及治疗抗性之间反式调控的“离岸包裹”
Noncoding RNA. 2017 Feb 23;3(1):10. doi: 10.3390/ncrna3010010.